Full coverageExperts Hail HIV Injection Breakthrough, Warn Cost Excludes Poor
By Racheal Abujah
Posts on X
Formerly Twitter
Gilead Sciences
GileadSciences
At Gilead, we're focused on delivering transformative therapies in #HIV and pushing the boundaries of scientific innovation in our mission to help end the epidemic. Here's what it takes. pic.x.com/r0rDCSjpjS
Posted on X
UNAIDS Global
UNAIDS
#PCB56 has started.
Ambassador Cecilia Kiku Ishitani, Chair of PCB, highlights the crisis in the global HIV response and applauds Member States and partners for stepping up. She calls for breakthrough prevention #Lenacapavir to be accessible and affordable.
@DelBrasGen pic.x.com/V7LUX6acLq
Posted on X
Unitaid
UNITAID
Unitaid is working with partners to make generic lenacapavir available quickly and affordably. Approvals mean little without access. Thanks @evolambert for an in-depth look at what’s needed next in @NPR’s excellent coverage.
Learn more: www.npr.org/sections/goats-and-soda/2025/06/18/g-s1-73130/hiv-prevention-drug-lenacapavir-fda-breakthrough
Posted on X
blkwomenshealth
blkwomenshealth
A breakthrough in HIV prevention! The FDA approved lenacapavir, and just 2 injections a year could provide near-complete protection from HIV. A game-changer for accessibility and reducing stigma. 🙌🏾
www.npr.org/sections/goats-and-soda/2025/06/18/g-s1-73130/hiv-prevention-drug-lenacapavir-fda-breakthrough pic.x.com/CKs4YAUeQw
Posted on X
All coverage
FDA approves HIV medication Lenacapavir, but it's costly
By Jonathan Lambert
Physician Views Preview: As Gilead 'PrEPs' for new era with Yeztugo, the focus turns to prescribers
By Jessica D'Amico
Breakthrough in HIV prevention LENACAPAVIR OFFERS NEW HOPE
By Ivninder Pal Singh
Not a licence to be wild
By Corey Robinson
Cost Will Be Massive Barrier in Access to Lenacapavir After Approval in the US: Gordon Crofoot, MD, PA
By Julia Bonavitacola
With Lenacapavir 'You've Basically Got a Vaccine.' But Reaching the People Who Would Benefit Is Difficult, Says Gates Foundation Expert
By Logan Lutton and Peter Wehrwein
Here’s what everyone should know about this new HIV prevention shot
By Teddy Amenabar and Richard Sima
Regulators Approve a Twice-Yearly Shot to Prevent H.I.V. Infection
By Apoorva Mandavilli
6 things to know about lenacapavir, what experts call a ‘wonder drug’ for preventing HIV
By Laura Santhanam
Another tool in the fight against HIV — and more
By Lourdes Duarte, Patrick Elwood and Katharin Czink
Successful clinical trials for two injection a year for HIV treatment, with no side effects
By Sudeshna Panda
New HIV Prevention Drug Approved—Now Let’s Remove the Final Barrier
By Jeffrey A. Singer
Groundbreaking twice-a-year HIV drug that could stop transmission approved
By Lauran Neergaard
FDA approves new twice-yearly HIV shot. What to know
By Ken Alltucker
US FDA approves Gilead's twice-yearly injection for HIV prevention
By Deena Beasley and Julie Steenhuysen
FDA approves twice-a-year injection for HIV prevention
By Jacqueline Howard
FDA approves Gilead's twice-yearly HIV prevention injection, offering a powerful and convenient new option
By Annika Kim Constantino
FDA Approves “Breakthrough” HIV Drug
By Jackie Flynn Mogensen
HIV prevention drug hailed as a 'breakthrough' gets FDA approval : Goats and Soda
By Jonathan Lambert
HIV protection with just two shots a year: FDA approves Gilead drug
By Ed Silverman and Jason Mast